Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Neoplasms 7Leukemia, Lymphocytic, Chronic, B-Cell 7Primary Myelofibrosis 6Solid Tumors 4Lymphoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Non-Hodgkin 2Leukemia, B-Cell 2Thrombocythemia, Essential 1Solid Tumor 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Polycythemia Vera 1Myeloproliferative Disorders 1Mycosis Fungoides 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoid Malignancy 1Leukemia, Myelomonocytic, Chronic 1Leukemia 1Hematologic Neoplasms 1

Interventions

zanolimumab 3mogamulizumab 3denileukin diftitox 2Vorinostat 2Vitamin B 12 2Panobinostat 2Folic Acid 210-propargyl-10-deazaaminopterin 2resminostat 1ontuxizumab 1navitoclax 1N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide 1MAC-ST-001 1Interleukin-12 Subunit p35 1Fentanyl 1Fenretinide 1Duration of Therapy 1Bexarotene 1A-dmDT390-bisFv(UCHT1) protein 1(N(1),N(12))bis(ethyl)-6,7-dehydrospermine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Sezary Syndrome × navitoclax × Clear all
NCT00406809 2021-08-02

A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies

AbbVie

Phase 1/2 Completed
81 enrolled
DermatologicLymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Mycosis Fungoides, Sezary Syndrome, Leukemia, B-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡